Urology 1998: Vol 51 Index

13 Pages·1998·3.5 MB·English

UROLOGY VOLUME 51, JANUARY TO JUNE 1998
Pages Issue Pages Issue
1-180 January 855-1078 June
181-354 February 2A-1-2A-48 February Supplement
355-524 March 4A-1-4A-66 April Supplement
525-676 April SA-1-5A-182 May Supplement
AUTHOR INDEX 677-854 May
Abdalla, 1., 300 Beduschi, R., 861 Caldamone, A.A., 5A-7, Crawford, E.D., 455, 675
Abdel-Meguid, T.A., 810 Beesley, C., 663 5A-15 Cresswell, M., 573
Abrahamsson, P.-A., 57, 585, Behar, R.J., 796 Callery-D’Amico, S., 610 Crook, J.M., 566
5A-141 Beiswanger, J.C., 125 Calvanese, C.B., 525 Crotty, K., 775
Abrams, J.H., 89 Belldegrun, A., 226, 367 Calvieri, S., 1046 Cummings, K.B., 632
Abrams, P., 1062 Campo, B., 506
Bellin, P., 697
Abu El Naser, M., 283 Cannon, J.M., 5A-170 Dahl, O., 833
Benavidas, A., 39
Agarwal, A., 306, 816 Cantor, A., 796 Dai, H., 39
Agha, A., 4A-58 Benet, A., 620 Carlson, G.D., 525 D’Aloia, G., 837
Akdas, A., 645 Benson, M.C., 226 Carroll, K., 389 Dalton, D.P., 831
Akiyama, K.-Y., 145 Bergstralh, E.J., 79 Carroll, P.R., 137, 226, 1018 D'Amico, A.V., 287, 449, 884
Albertini, J.J., 499 Berlin, B.B., 63 Carson, C.C., 548, 627 Dann, J., 697
Albertsen, P.C., 63, 161 Berman, J.R., 650 Cass, C.B., 573 Davis, R.S., 5A-167
Al Juburi, A.Z., 5A-170 Bernier, P.A., 242, 408 Catalona, W.J., 558 Day, J.R., 804
Alexander, R.B., 150 Bernini, G.P., 920 Celis, E., 150 Deaton, J.L., 125
Allerton,J. ,+ A-64 Besalti, O., 400 Cendron, M., 5A-3 Debruyne, F.M.J., 44
Alsaffer, N., 130 Bibbo, M., 956 Cevik, I., 645 Deftos, L.J., 5A-110, 5A-141
Anafarta, K., 400 Bihrle, W., 226 Chamberlain, M., 389 Degener, A.M., 1046
Anastasia, K., 105 Bissett, D., 130 Chancellor, M.B., 671 Deitch, A.D., 346
Anders, K.H., 119 Bjartell, A., 585 Chang, E., 287 Denis, L., 5A-50
Anderson, J.B., 389 Bjork, T., 57 Chassagne, S., 408 DenstedtJ,. , 19
Andrawis, R.I., 161 Blackledge, G.R.P., 389 Chaudhuri, T.K., 5A-175 de Reijke, Th., 44
Appell, R.A., 2A-24, 2A-27 Blaivas, J.G., 2A-11 Chee, C., 29 Desautel, M.G., 708, 1013
Arakawa, S., 460 Bloom, D.A., 168 Cheng, C., 29 Deutsch, T.F., 342
Arcangeli, C.G., 558 Cher, M.L., 789 Devere White, R.W., 346
Blumenstein, B., 675
Atala, A., 221 Childs, S., 697 DeWeese, T.L., 884
Blute, M., 79
Austria, A., 1013 Chin, LJ., 19 Dhabuwala, C.B., 324, 638
Blute, M.L., 731, 908
Aydos, K., 510, 1051 Cho, L., 335 Dianzani, C., 1046
Bogojavlensky, S., 697
Choan, E., 566 Diaz, P.A., 1013
Babaian, R.J., 132, 293 Bolton, S., 998 Chodak, G.W., 1003 Dimopoulos, M.A., 946
Baccala, A.A., 327 Bormes, T.P., 1049 Chosy, S.G., 5A-161 Di Sant’Agnese, P.A., 5A-
Bach, M., 4A-58 Bostwick, D.G., 79, 578, 749 Chovnick, S.D., 796 110, 5A-121
Badlani, G.H., 708, 1013 Boyd, J.C., 277 Chow, V.D.W., 251 Dmochowski, R.R., 960
Baert, L., 389 Boyd, S.D., 951 Christ, G., 640 Docimo, S.G., 99
Bagley, D., 956 Boyle, P., 428 Ciocca, R.G., 632 Dougias, T., SA-89
Bahnson, R.R., 840 Boynton, A.L., 5A-89 Clark, A.J., 116 Drach, G.W., 33
Balcolm, A.H., 5A-12 Brady, F., 150 Clark, PJ., 33 Drake, W.M., Jr., 671
Balcom, A.H., 317 Brant, M., 775 Clift, S.M., 327 Drose, J.A., 114
Bales, G.T., 1003 Brasso, K., 590 Coakley, F.V., 1018 Dubbink, H.J., 657
Baliga, M., 1040 Brausi, M., 506 Cobb, C.G., 33 Dubocgq, F.M., 324
Balsara, R.K., 1027 Brock, J.W., IL, 480 Cockett, A.T.K., 57, 5A-1, Dudley, A., 1018
Baltaci, S., 400 Brock, W.A., 313 5A-58, 5A-110, 5A-135, Dyaa Sallem, M., 283
Bancila, E., 632 Broder, S.R., 277 5A-170
Barada,J. , 697 Brodherson, M.S., 112 Cockett, W.S., 5A-1 Edstrom, L.E., 5A-15
Barnboym, E., 242 Colditz, G.A., 422 Eibenberger, K., 534
Brown, B., 335
Barnhill, $.D., 132 Collings, D., 197 Elbadawi, A., 5A-62, 5A-73
Brown, J.A., 322, 715
Barrett, D.M., 254, 715 Collins, L., 5A-58 Elbaz, M.A., 469
Brown, S., 242
Barry, MJ., 422 Colon, E., 158 El Faqih, S.R., 544
Bruskewitz, R.C., 12, 381,
Bartsch, G., 5A-89 Coltman, C.A., jr., 4A-64 El-Galley, R., 283
415, 731, 4A-13, 4A-23
Barzell, W., 19 Conlon, K.C., 122 Elliott, D.S., 715
Baschinsky, D.Y., 840 Bucci, M., 1046 Connelly, R.R., 970 Ellis, W.J., 226
Ba-Ssalamah, A., 534 Budd, H.A., 443 Constantino, G., 5A-179 Ely, M.G., 63
Bassler, I.C., 749 Bukowski, R.M., 933 Contreras, B.A., 1003 Emanuel, E.R., 86
Bassler, T.J., 749 Bulusu, A.D., 487 Coogan, C.L., 1049 Engel, J.D., 687
Bauer, J.J., 158, 846, 917, Burney, T.L., 1013 Corn, B.W., 782 Ennis, R.D., 265
970 Burzon, D.T., 5A-27 Cote, R.J., 951 Enquist, H., 342
Baum, N., 355 Bussani, R., 837 Cox, C., 5A-58 Epstein, J.1., 525, 759, 820
Beduschi, M.C., 861, 5A-98 Butler, R., 197 Cox, C.E., Il, 610 Erdem, E., 1051
© 1998, ELseviER SCIENCE INC. 0090-4295/98/$ 19.00
ALL RIGHTS RESERVED PIL SO090-4295(98)00164-2 1065
Erden, E., 510 Gomella, L., 782 Hufnagel, H.V., 553 Kneib, T.G., 960
Erton, M.L., 645 Gomella, L.G., 810 Huland, E., 437 Knispel, H.H., 94
Erturk, E., 5A-27 Gonzalez, C.M., 831 Huland, H., 437 Knoll, D., 697
Esche, B.A., 566 Gonzalez, R., 99 Hulbert, W.C., 5A-15, Knoll, L.D., 89, 271
Esrig, D., 951 Goodacre, B., 320 5A-20, 5A-23 Koch, M.O., 197
Evans, C.L., 804 Gormley, G., 4A-58 Humphrey, P.A., 558 Koenig, F., 342
Gotting-Smith, K., 389 Hyslop, T., 782 Kohn, L.J., 1027
Fantl, J.A., 2A-30 Grabenwoger, F., 534 Kojima, M., 293, 722
Fenster, H.N., 251 Graefen, M., 437 lacconi, P., 920 Kollias, N., 342
Feraren, R.E., 708 Gregory, A., 242 Iczkowski, K.A., 749 Kolm, P., 5A-175
Ferguson, K., 516 Grignon, D., 789 Inoue, Y., 849 Komo, D., 39
Ferrer, F.A., 161 Grignon, DJ., 324 lokim-Liossi, A., 946 Konichezky, M., 539
Fiedler, U., 94 Grimaldi, G., 122 Irby, P.B., 917 Koyle, M.A., 5A-15
Finasteride PSA Study Groshen, S., 951 Israel, L., 464 Kraklau, D., 168
Group, 4A-58 Grossfeld, G.D., 137, 951 Issa, M.M., 105, 415 Kramolowsky, E., 271
Fink, S., 5A-175 Guess, H.A., 428 Iversen, P., 389, 590 Kranse, R., 558
Finlay, J.A., 804 Guo, M., 1040 Iwamura, M., 5A-110 Krarup, T., 4A-58
Fisch, H., 86 Gurganus, R., 759 Kreutzer, D.L., 161
Fishback, N., 553 Gtiven, C., 1051 Jabbour, M.E., 1008 Kreuzer, S., 534
Fishman, E.K., 3 Jackson, S.E., 874 Krishnamurthi, V., 933
Flanagan, M.J., 1049 Haab, F., 408 Jacobsen, S.J., 213, 428, 578 Kriteman, L., 397
Fleischmann, J., 640 Haas, C.A., 516 Jacobson, D.J., 213 Kruger Kjeer, S., 590
Fleming, M.P., 39 Haese, A., 437 Janosko, E.O., 627 Kryger, J.V., 1033
Forman, J.D., 998 Hafez, R.G., 635 Jarow, J.P., 67, 125 Kubak, B., 119
Foster, C.S., 663 Hahnfeld, L.E., 404 Jayson, M., 203 Kunnel, B., 186, 531
Fowler, C.L., 610 Hajjar, J.H., 443 Jeffs, R.D., 99 Kunnel, B.S., 749
Fowler, J.E., Jr., 1040 Hammerer, P., 437 Jensen, D., 833 Kuntzman, R.S., 254
Frank, I.N., 5A-58 Hamond, C., 63 Jepsen, J.V., 12, 381, 4A-13, Kupeli, B., 510, 1051
Fraundorfer, M.R., 573 Hampel, N., 516 4A-23 Kupeli, S., 510, 1051
Freeman, J.A., 951 Hancock, R.J.T., 5A-146 Jiborn, T., 585 Kupelian, P.A., 766
Freeman, R.B., 5A-156 Hanks, G.E., 985 Jiminez, V.K., 105 Kurita, Y., 595
Freid, R.M., 5A-131 Hanlon, A.L., 985 Jiroutek, M., 287 Kurtzman, S.H., 161
Freiha, F.S., 339 Harle, B., 94 Johansen, T., 4A-58 Kuus-Reichel, K., 804
Freyle,J. , 501 Harmon, TJ., 558 Jorgensen, T., 590 Kwon, D.D., 744
Friis, $., 590 Harrison, H.L., 492 Juttner, H.U., 39 Kyprianou, N., 650
Fritsche, H.A., 132 Hawthorne, C., 956
Fritzsch, R., 19 Hayes, W.S., 39 Kabalin, J.N., 573 Lagerkvist, M., 4A-58
Fuchs, E.F., 927 Hayyeri, M., 616 Kagawa, S., 145, 849 Lai, M.-K., 5A-125
Fujisawa, M., 460 Heinz-Peer, G., 534 Kahane, H., 525 Langlois, N.E.I., 130
Fujita, K., 595 Heisey, D.M., 404 Kaisary, A.V., 389 Larne, R., 342
Furukawa, A., 145, 849 Heitjan, D.F., 265 Kamidono, S., 460 Larson, T.R., 731, 908
Helal, M.A., 499 Kanayama, H.-O., 145, 849 Lash, C., 829
Gambill, N.B., 327 Heller, K.N., 495 Kanda, K., 849 Lashley, D.B., 927
Gandour-Edwards, R., 346 Hendin, B.N., 816 Kantoff, P., 287 Laudone, V.P., 63, 161
Ganem, J.P., 548, 627 Henke, R.-P., 437 Kanzaki, M., 460 Lebos, L., 197
Ganz, M.B., 516 Herbert, F.B., 320 Kaplan, G.W., 183 Lee, B.R., 820
Garg, M.K., 998 Herold, D.M., 985 Kaplan, S.A., 4A-32 Lee, F.T., Jr., 5A-161
Garnick, M., 287 Herr, H.W., 489 Karakitsos, P., 946 Lee, J.-C., 306
Garraway, W.M., 428 Higgins, B., 4A-64 Kaufman, H.S., 917 Leffell, M.S., 150
Gayer, E., 539 Hirasing, R.A., 1022 Kavoussi, L.R., 917 Legg, E.A., 320
Gearhart, J.P., 820 Hirsch, I.H., 810 Kawachi, I., 422 Lehman, H., 501
Gentile, D.P., 5A-20 Ho, C.K., 158 Ke, Y., 663 Lemos, L.B., 1040
Gerber, G.S., 1003 Hochberg, D.A., 112 Keetch, D.W., 558 Lepor, H., 892, 901
Gershagen, S., 5A-110 Holcomb, G.W., III, 480 Kelly, W.K., 489 Leppaniemi, A.K., 553
Gettman, M.T., 79 Hollabaugh, R.S., Jr., 960 Kenny, G.M., 5A-89 Levesque, P.E., 978
Gheiler, E.L., 789 Holmes, E.H., 5A-89 Kerr, L.A., 495 Levin, H.S., 766, 816
Gilbaugh, J., Jr., 5A-89 Holtgrewe, H.L., 4A-1, Kessler, O.J., 313, 539 Libertino, J.A., 978
Gilling, P.J., 573 5A-31 Kim, B., 1018 Lieber, M.M., 213, 428, 578
Ginsberg, D.A., 128, 951 Holthaus, K., 455 Kim, H.N., 744 Lieskovsky, G., 951
Giovannucci, E., 422 Hom, D., 708 Kim, SJ., 744 Lilja, H., 57
Girman, C.J., 428, 578, 4A-8 Hong, Y., 335 Kim, S.S., 610 Lippert, M.C., 277
Gladden, K.H., 5A-175 Hop, W.CJ., 51 King, W., 610 Lish, M.C., 824
Glass, L.L., SA-135 Hopkins, T., 487 Kingston, T.E., 5A-7 Ljungberg, B., 57
Gleave, M.E., 137, 251 Howhannesian, A., 443 Klein, E.A., 232, 766 Lockhart, J.L., 499
Goessl, C., 94 Hricak, H., 1018 Klima, W,J., 1008 Lohrasbi, F.F., 492
Golden, R.M., 335 Hu, T.-W., 355 Klimberg, I.W., 610 Lovato, L., 4A-64
Goldenberg, S.L., 251 Huang, A., 346 Klinger, C.H., 206 Lowe, F.C., 1003
Goldfischer, E.R., 855, 1008 Hudson, M.A., 226 Klocker, H., 5A-89 Lucey, D.T., 627
Goluboff, E.T., 86 Huff, W., 796 Klutke, C.G., 835 Lue, T.F., 874
1066 UROLOGY 51 (6), 1998
Lumerman, J.H., 708 Moore, R.G., 917 Pang, X., 939 Rhodes, T., 428, 578
Lyell, M.S., 103 Moretti, A., 920 Pantazopoulos, D., 946 Rich, N.M., 553
Morey, A., 1018 Park, J.M., 601 Richard, F., 428
Morgan, T., 5A-89 Park, Y.1., 744 Rigatti, P., 506
Macchia, R.J., 616
Morgan, W.M.., III, 480 Parma, A., 506 Riley, J.R., 33
Mackenzie, $.H., 455
Morreale, J.F., 5A-58 Partin, A.W., 181, 759, 820 Rittenhouse, H.G., 804
Mackey, J.R., 1043
Moskovitz, B., 693 Passe, T.J., 327 Rivas, D.A., 671
Madersbacher, S., 206
Mostafavi, M.R., 484 Patel, B., 816 Roberts, R.O., 213, 578
Madjar, S., 693
Motta,J. , 112 Payne, C.K., 1062, 2A-3, Robertson, S., 566
Madyastha, K.R., 132
Moul, J.W., 158, 970 2A-35 Robinson, R.D., 5A-58
Maier, A., 534
Movsas, B., 985 Payne, J.K., 804 Robson, W.L.M., 477
Malcolm, A., 573
Mukamel, E., 539 Pearle, M.S., 33 Roehrborn, C.G., 19, 33,
Malek, R.S., 254
Mulholland, S.G., 671, 782 Peehl, D.M., 657 242, 408, 415, 4A-19,
Malkowitz, S.B., 449
Miller, $.C., 99 Peelen, P., 44 4A-46
Malyszko, B.K., 265
Mun, S.K., 39 Peerboom, D., 232 Romijn, J.C., 657
Mangone, C., 501
Muraishi, O., 1031 Perez, R., 796 Rosenthal, S.A., 346
Manyak, M.J., 226, 495
Murphy, D.P., 632 Perez-Marrero, R., 415 Rovner, E.S., 128
Marberger, M., 206
Murphy, G.P., 5A-89 Perlmutter, A., 19 Roy, J., 4A-58
Marberger, M.J., 677
Mydlo, J.H., 616 Perry, G.A., 566 Rozanski, T.A., 827
Marshall, F.F., 3, 327
Persad, S.G., 39 Rubin, M., 265
Masuda, H., 595 Naitoh,J. , 367 Pettersson, K., 57 Russo, M.A., 5A-36
Matkov, T.G., 1049 Nakada, S.Y., 404, 1033, Pierangeli, A., 1046 Russo, P., 122
Matsumoto, T., 145 5A-161 Piironen, T., 57 Ruud Bosch, J.L.H., 51
Maximo, C.B., 840 Nakamura, R.M., 5A-83 Pikoulis, E., 553 Ryu, S.B., 744
Mayer, R.D., 731 Narayan, P., 415, 4A-38 Pizzocaro, G., 506
Mazza, G., 506 Naslund, M.J., 415 Plaino, F., 837
McCarthy, M.M., 650 Nativ, O., 693 Pointner,J. , 5A-89 Sabo, E., 693
McCullough, D.L., 67 Neal, D.E., Jr., 320 Polascik, TJ., 884 Sagalowsky, A.1., 2 26
McFadden, J.C., 829 Nelson, W.G., 327 Poll, W., 697 Sagnier, P.-P., 428
McGovern, F.J., 342 Netto, I.C.V., 5A-175 Pollack, A., 258, 991 Saidi, J.A., 1035
McGuire, E.J., 168 Newhall, P., 19 Pontes, E., 998 Sakr, W., 789
McKenna, B.A., 5A-156 Nguyen, L.N., 991 Pontes, J.E., 324, 789 Salazar, F., 827
McKiel, C.F., Jr., 1049 Nickel, J.C., 362, 4A-50 Poore, R.E., 67 Sall, M., 381
McLeod, D.G., 158, 846, Niederberger, C.S., 335 Porter, A.T., 998 Saltzman, B., 484
970, 5A-89 Nieh, P.T., 978 Pouliakis, A., 946 Salvetti, A., 920
McLoughlin, M.G., 251 Niemann, T.H., 840 Pound, C.R., 884 Sanda, M.G., 884
McNeal, J.E., 749 Nishitani, M., 849 Pranikoff, K., 5A-179 Sanders, H., 203, 283
McVary, K.T., 687 Noldus,J. , 437 Prasad, P.V., 484 Sanders, J., 19
Meacham, R.B., 114 Norman, R.W., 116 Preminger, G., 19 Sanders, W.H., 397
Melman, A., 620, 640 Nouri, A.M.E., 5A-41 Preminger, G.M., 33 Sant, G., 939
Meng, J., 221 Novick, A.C., 933, 1057 Prestigiacomo, A.F., 412 Sarosdy, M.F., 226
Merguerian, P.A., 5A-3, Sauvageot, J., 759
Preston, D.M., 970
5A-12 Obek, C., 73 PROWESS Study Group, Schalken, J.A., 44
Mesrobian, H.-G. O., 317 Oberpenning, F., 221 Puchner, P.J., 237, 1035 Schamhart, D.H.J., 44
Messing, E., 381 O'Bryan, M.K., 464 Pycha, A., 206 Schatzl, G., 206
Messing, E.M., 5A-58 Ochiai, A., 722 Schiff, P.B., 265
MeulmeesteJr.,F. , 1022 O’Connell, MJ., 5A-58 Schlegel, P.N., 464
Mevorach, R.A., 5A-3, 5A-12 O'Donnell, P.D., 2A-20, Rabinovitch, H., 1027 Schmidt, D., 381
Mian, C., 206 2A-40 Rabinowitz, R., 5A-7, 5A-15, Schnall, M., 449
Miccoli, P., 920 O'Dowd, G., 186 5A-20, 5A-23, 5A-27 Schomacker, K.T., 342
Michaels, E.K., 335 O'Dowd, G.J., 531 Radder, J.J., 1022 Schréder, F.H., 51, 558, 657
Michaels, M.J., 824 Oefelein, M.G., 775 Radhakrishnan, J., 829 Schulam, P.G., 917
Michl, U., 437 Oesterling, J.E., 415, 861, Ragde, H., 5A-89 Schultz, D., 449
Mikolajczyk, S.D., 804 4A-58, 5A-98 Ravinthiran, T., 29 Schurmans, J.R., 51
Milikowski, C., 1037 Oh, B.R., 744 Ray, P., 300 Schwob, V.S., 749
Millar, L.S., 804 Okada, H., 460 Ray, V., 300 Seay, T., 4A-64
Miller, D.A., 197 Okuda, Y., 460 Rayhill, $.C., 404 Sech, S., 19
Miller, K., 94 Olencki, T., 232 Raz, S., 128 Sech, S.M., 33, 242
Miller, L.E., 105 Onel, E., 63 Razmjouei, K., 516 Seftel, A.D., 516
Miller, L.J., 161 Optenberg, S., 4A-64 Razvi, H., 19 Seigne, J.D., 499
Miller, M.C., 186 Orloff, M., 5A-27 Reeder, J.E., 5A-58 Seldin, D.W., 978
Miller, M.I., 237 Orozco, R., 186, 531 Rehman, J., 620, 640 Serra, A.D., 1018
Minette, L.J., 477 Orozco, R.E., 749 Reilly, W.T., 213 Servadio, C., 539
Misrock, S.L., 5A-89 Otheguy,J. , 796 Reisch, J.S., 408 Sesterhenn, I.A., 158, 970
Mohler, J.L., 824 O'Toole, K.M., 265 Reiss, A., 693 Shaaban, A.A., 469
Montague, D.K., 874 Ozer, E., 400 Reissigl, A., 5A-89 Sharifi, R., 271
Montie, J.E., 601 Ozer, G., 400 Rescigno,J. , 265 Sharkey, F.E., 226
Montoya, J.D., 242 Resnick, M.I., 277 Sharkey, J., 796
Moon, J.D., 744 Pabico, R.C., 5A-156 Rhodes, N.P., 663 Sharma, R.K., 306
Moon, T.D., 5A-161 Pahira, J.J., 39 Rhodes, P.R., 381 Shekarriz, B., 638
UROLOGY 51 (6), 1998
Shelfo, S.W., 73 Sturbaum, C.W., 317 Tuason, L., 766 Weiss, G.H., 5A-131
Shen, J., 657 Sujka, S.K., 499 Tulunay, O., 510 Weiss, R.E., 632
Shepherd, D.L., 558 Sullivan, L.D., 251 Turkeri, L.N., 645 Weiss, S.G., II, 635, 1033
Shirazian, D., 501 Sumiyoshi, Y., 145 Tuttle,J. ,6 97 Welch, G., 422
Shortliffe, L.D.S., 5A-3 Suzuki, K., 595 Tyrrell, CJ., 389 Wesselhoeft, C., 5A-7
Shown, T., 4A-58 Swanson, S.K., 322 Wheeless, L.L., 5A-58
Shumaker, B.P., 415 Symes, M.O., 5A-41 Uehling, D.T., 635, 1033 Wherry, D.C., 553
Siders, D.B., 346 Ugarte, R.R., 731 Whitlock, S.V., 908
Sidhu, R.S., 306 Tabbara, S.O., 495 Unsal, A., 510, 1051 Whitman, A.E., 265
Siegel, D., 5A-131 Takihara, H., 5A-150 Upadhyay,J. , 638 Whitmore, W., 19
Siegel, J.F., 313 Talic, R.F., 544 Utz, WJ., 731 Whittington, R., 449
Silver, R.1., 99, 820 Talley, NJ., 213 Uznis, G., 168 Willet, W.C., 422
Simon, M.A., 1037 Talluri, G., 501 Williams, B.R.G., 1057
Simons, J.W., 327 Tammela, T., 389 Vaida, F., 300 Wills, M.L., 759
Singer, A.J., 119 Tamsulosin Investigator Valicenti, R.K., 782 Wise, GJ., 501
Siracusano, S., 837 Group, 892, 901 Van Balken, M.R., 44 Witjes, J.A., 44
Skinner, D.G., 443, 951 Tarantino, A.E., 63 Van Der Poel, H.G., 44 Wolchok, J.D., 489
Slaughenhoupt, B.L., 492 Tchetgen, M.-B., 333 Van Savage, J.G., 317, 492 Wolf, J.S., Jr., 333, 859
Small, E.J., 137 Tefilli, M.V., 324, 789 Vasavada, S.P., 1057 Wolfert, R.L., 804, 5A-89
Smith, A.D., 855, 1008, 5A- Tekyi-Mensah, S., 998 Velasco, J., 998 Womack, S., 19
131 Tempany, C.M., 287 Veltri, R.W., 186 Won, Y.H., 744
Smith, D.S., 558 Terada, H., 595 Venner, P., 1043 Wonsetler, B., 39
Smith, E.M., 5A-175 Terris, M.K., 339, 412 Vicini, A., 506 Wood, D.P., Jr., 789, 998
Smith,J. , 271, 697 Tewari, A., 4A-38 Vijayakumar, S., 300 Wright, J.E., 251
Smith, J.A., Jr., 197 Theodorescu, D., 277 Vivaldi, M.S., 920 Wu, G., 5A-110
Smith, P., 663 Theoharides, T.C., 939
Smith, P.A., 3 Thomas, A.J., Jr., 816 Wachtel, Z., 443 Yang, Z., 5A-58
Solc, Z., 796 Thomason, M.A., 477 Wagner, T.H., 355 Yerkes, E.B., 480
Sollinger, H.W., 404 Thompson, I., 675, 4A-64 Wainstein, M.A., 835 Yoo, J.J., 221
Soloway, D., 1037 Thompson, I.M., 827 Wald, M., 693 Youssef, A.R., 5A-170
Soloway, M., 73 Tiguert, R., 789 Waldstreicher, J., 4A-58 Yu, H.-J., 5A-125
Soloway, M.S., 1037 Tohme, W.G., 39 Walsh, P.C., 884
Sorbye, H., 833 Tokue, A., 1031 Walsh, R.A., II, 114 Zagaja, G.P., 1003
Soygur, T., 400, 510, 1051 Tolunay, O., 1051 Ward, A.M., 232 Zagars, G.K., 258, 991
Spee-van der Wekke, J., Tomaszewski, J.E., 449 Warner, T., 5A-161 Zanon, M., 837
1022 Townsend, M., 105 Wasson, J.H., 63 Zhang, K.H., 132
Srivastava, S., 158, 970 Tri, J.L., 908 Watschinger, B., 534 Zhang, Y., 657
Stamey, T.A., 412, 531 Tribukait, B., 469 Webber, R.J.S., 130 Zhang, Z., 132
Steffen-Wilke, K., 94 Trombetta, C., 837 Weijerman, P.C., 51, 657 Zhong, H., 327
Stein, J.P., 443, 951 Troncoso, P., 293 Wein, A., 449 Zimmerman, R.L., 956
Steiner, M.S., 960 Tsai, V., 150 Wein, A.J., 1062, 2A-1, 2A- Zimmern, P.E., 408
Stenner,J. , 455 Tschumper, B., 1018 43 Zincke, H., 79
Stephen, R.L., 506 Tsuji, M., 849 Weiner, D.M., 1035 Zini, A., 464
Stravodimos, K.G., 1008 Tsukamoto, T., 428 Weinstein, R., 539 Zinman, L.N., 978
UROLOGY 51 (6), 1998
SUBJECT INDEX Arterial hemodynamics, penile, penile ultrasonic
velocitometry versus penile duplex ultrasonography,
89
(Page numbers in the Supplement to the February issue are Aspergillosis, testis, in renal transplant recipient, 119
preceded by a “2A-”, to the April issue by a “4A-”, Azoospermia, obstructive, in male infertility, treatment, 5A-
and to the May issue by a “5A-”.) 150
Acinar proliferation, predictive value for cancer, 749 Bacille Calmette-Guérin, oral bromocriptine
Acute abdomen, postoperative urologic patient, laparoscopy, immunotherapy, of bladder carcinoma in situ after,
917 226
Adenocarcinoma Baldness, male pattern, benign prostatic hyperplasia, 744
arising within testicular metastasis, 632 Bard BTA test, upper urinary tract transitional cell
bladder, deoxyribonucleic acid flow cytometric and carcinoma detection, 956
morphologic characterization, 469 Bax expression, renal cell carcinoma, 1057
continent colonic urinary reservoir, 499 Bcl-2
prostate expression, renal cell carcinoma, 1057
outpatient ultrasound-guided pallidum 103 immunohistochemical alterations in prostate cancer
brachytherapy, 796 treated with radiation therapy, 346
stage T2, recurrence, microvessel density analysis, 73 prostate cancer familial history, 970
Adenoid cystic carcinoma of salivary gland, bilateral Behavioral intervention, for urinary incontinence, 2A-30,
synchronous renal metastases post resection, 322 2A-40
Adrenal gland Bicalutamide, compared with castration in nonmetastatic
contralateral, metachronous renal cell carcinoma prostate cancer, 389
metastasis to, 539 Biofeedback, for urinary incontinence, 2A-35
masses, large, hormonal and morphologic evaluation, 920 Biopsy. See Gleason score; Prostate biopsy
Adrenalectomy, laparoscopic, transabdominal and Bladder
retroperitoneal approach, experience with, 29 catheterization. See Catheterization
Age leiomyoma, epithelioid, voiding symptoms, 1037
erectile dysfunction, endothelial nitric oxide synthase, 516 overactive
lower urinary tract changes, gender and, 206 epidemiology, pathophysiology, and evaluation, 2A-3
positive prostate biopsy rate, prostate-specific antigen pharmacologic options, 2A-43
level, 531 surgery for, 2A-27
prostate cancer metastases, 985 Bladder augmentation using allogeneic bladder submucosa
Air Force leadership, Prostate Cancer Prevention Trial, seeded with cells, 221
4A-65 Bladder cancer
Alkaline phosphatase levels, in bone metastasis due to renal adenocarcinoma, deoxyribonucleic acid flow cytometric
cell carcinoma, 397 and morphologic characterization, +69
Allogeneic bladder, bladder augmentation using, 221 locally advanced, continent diversion after cystectomy in,
Alpha, ,-adrenergic antagonists, benign prostatic 232
hyperplasia, 861 oral bromocriptine immunotherapy after bacille Calmette-
Alpha, -antichymotrypsin, PSA complexed to, elimination Guérin, 226
from serum, compared with free prostate-specific squamous cell carcinoma causing hypercalcemia and
antigen, 57 inhibition of PTH secretion, 489
Alprostadil, transurethral, failed prior intracavernosal superficial, prognosis, expression of epidermal growth
injection, 687 factor, transforming growth factor alpha, and
Ambulatory care epidermal growth factor receptor, 640
radical retropubic prostatectomy, 443 transitional cell carcinoma with mucinous differentiation,
ultrasound-guided palladium 103 brachytherapy, fine needle aspiration of penis, 1040
adenocarcinoma of prostate, 796 Bladder cancer detection
American Urological Association symptom scores among bladder wash cytology, quantitative cytology, and
men and women with urinary incontinence, 213 qualitative BTA test for, 44
American urology, managed care impact, 5A-31 DNA cytometry, chromosome 9 aberrations by
Amitriptyline, urinary frequency and pain, 5A-179 fluorescence in situ hybridization of irrigation
Androgen ablation therapy, prostatic carcinoma, specimens, 5A-58
neuroendocrine differentiation, 585 spectroscopic measurement of diffuse reflectance, 342
Androgen deprivation Bladder cancer treatment
neoadjuvant, assessment of prostate cancer volume using cystectomy, specimens, orthotopic diversion, 951
endorectal coil magnetic resonance imaging, 283 intravesical electromotive administration of drugs for
for prostate cancer, 137 superficial cancer, 506
Angiogenesis factor, in prostate cancers, 161 Bladder diversion, orthotopic, incontinence and retention
Angiography. See Magnetic resonance angiography after, 601
Angiomyolipoma, kidney, and oncocytoma, 837 Bladder neck
Angiosarcoma, of penis, 130 preservation, during radical retropubic prestatectomy,
Apoptosis, in rat vagina, effect of estrogen withdrawal on, impact on pathologic outcome, anastomotic
650 strictures, and continence, 73
Army leadership, Prostate Cancer Prevention Trial, +A-65 purse-string cuff, for incontinence in children with
Arrhythmias. See Cardiac arrhythmias myelodysplasia, 1027
© 1998, ELsevieR SCIENCE INC. 0090-4295/98/$ 19.00
ALL RIGHTS RESERVED PIL SO090-4295(98)00166-6 1069
Bladder outlet obstruction, in women, proposed cutoff impact of bladder neck preservation during radical
values to define, 408 retropubic prostatectomy on, 73
Bladder, overactive (letter), 1062 Continence shield, CapSure (Re/Stor), urinary stress
Bladder pseudotumor, inflammatory, 487 incontinence, 697
Bladder wash cytology, for superficial bladder cancer Continent diversion, in locally advanced bladder cancer, 232
detection, 44 Continent nerves preservation, radical retropubic
Bladder weight, ultrasound estimated, correlation with prostatectomy, urinary continence, 960
ultrasonic appearance of prostate and postvoid Corpora cavernosa, high flow malignant priapism isolated
residual urine in men with lower urinary tract metastasis to, 324
symptoms, 722 Costs, urinary incontinence, 355
Bone anchors, Vesica, pubovaginal sling, 708 Craniospinal irradiation, seminoma with isolated central
Bone metastasis, due to renal cell carcinoma, alkaline nervous system relapse salvage, 1043
phosphatase levels, 397 Cryosurgery, laparoscopic, kidney, porcine model, 5A-161
Bromocriptine, oral immunotherapy of bladder carcinoma in Cyst
situ after bacille Calmette-Guérin, 226 seminal vesicle, associated with ipsilateral renal agenesis
BTA test, for superficial bladder cancer detection, 44 and ectopic ureter, endoscopic transvesical incision,
Buccal mucosal grafts, for urethral reconstruction, 5A-15 831
testicular, interstitial spermatocele, 5A-167
Cystadenoma, seminal vesicle, 840
c-kit, altered expression in interstitial cystitis, 939
Cystectomy
Calculi
continent diversion in locally advanced bladder cancer
bladder, in kidney-pancreas transplant recipients,
after, 232
endourologic therapy for, 404
specimens, female, orthotopic diversion, 951
growth after shock wave lithotripsy, neural network to
Cystic disease of kidneys
predict, 335
in renal transplant recipients, magnetic resonance
renal and ureteral, Alexandrite laser for, safety and
imaging, 534
efficacy of, 33
renal tubular dysfunction, 5A-156
Candidemia, in patients with candiduria, polymerase chain
Cystic dysplasia, testis, multicystic dysplasia of kidney, +77
reaction, 501
Cystic renal neoplasm, multilocular cystic renal cell
Carcinoma in situ, bladder, oral bromocriptine
carcinoma, 635
immunotherapy after bacille Calmette-Guérin, 226
Cystitis, interstitial
Cardiac arrhythmias, external fixed-rate signal generators in
altered expression of bladder mast cell growth factor
shock wave lithotripsy with Medstone Lithotriptor,
receptor, 939
548
pentosanpolysulfate, 381
Casodex. See Bicalutamide
Cystitis glandularis, 112
Castration, compared with Casodex in nonmetastatic
Cystolitholapaxy, for bladder calculi in kidney-pancreas
prostate cancer, 389
transplant recipients, 404
Catheter, suprapubic, placement, Lyell Sound for, 103
Cystostomy, suprapubic, Lyell Sound for, 103
Catheterization, bladder, direct vision, short rigid
Cytometrics, clinical, Frederic C. McLellan and, 168
ureteroscope, 827
Cavernosal artery, injury, high flow priapism secondary to,
imaging of, 114 Decision-making, shared, in prostate cancer, 63
Cavernosography, penile fractures, 616 Denmark, prostate cancer incidence and mortality in, 590
Cavernous nerve, physical and electrical stimulation, Deoxyribonucleic acid, human papillomavirus type 18
intracavernous pressure responses, 640 immortalized prostate cell lines, expression of
Cavernous pressure, responses to physical and electrical prostatic factors measured by reverse transcriptase
stimulation, 640 polymerase chain reaction, 657
Censoring of patients during benign prostatic hyperplasia Deoxyribonucleic acid flow cytometry, bladder
treatment trials, conditional regression to the mean adenocarcinoma, 469
induced by, “placebo effect” in, 242 Detrusor hyperreflexia, urodynamic effects of oral
Chromosome 9 aberrations by fluorescence in situ oxybutynin chloride in children with, 94
hybridization of irrigation specimens from bladder Detrusorrhaphy, unilateral vesicoureteral reflex in children,
cancer patients, 5A-58 5A-12
Cold light illumination system, Storz, 5A-1 DNA cytometry, of irrigation specimens from bladder cancer
Colic. See Renal colic patients, 5A-58
Collagen Drake, Willard M., Jr., invention of modern uroflowmeter
cystoscopic injection, periurethral pseudocyst following, by, 671
835
subtypes, histologic analysis, primary obstructed and
refluxing magaureter of childhood, 820 Ejaculation, effect on prostate-specific antigen, in prostate
Computed tomography, spiral, renal, 3 cancer-screening population, 455
Computer-assisted semen analysis, accuracy of, in prefreeze Ejaculatory duct, obstruction, partial, causing early demise
and post-thaw specimens, 306 of sperm, 125
Congenital nephrotic syndrome of Finnish type, urologic Elderly, urinary incontinence, 2A-20
management, 492 economic costs, 355
Consulting service, Telemedicine, for evaluation of Electrical stimulation, for urinary incontinence, 2A-24
urolithiasis, 39 Electromotive administration of drugs, intravesical,
Continence, urinary superficial bladder cancer, 506
after radical retropubic prostatectomy, puboprostatic Embolization, arterial, for blunt trauma to horseshoe kidney,
ligament sparing improvement of, 67 320
1070 UROLOGY 51 (6), 1998
Endopyelotomy Hematolymphoid malignancies, prostate, transrectal
(editorial), 855 ultrasound appearance, 339
retrograde Acucise (editorial), 859 Hematuria, associated with benign prostatic hyperplasia,
Endoscopy, transvesical incision, seminal vesicle cyst effects of finasteride on, 237
associated with ipsilateral renal agenesis and ectopic Hemorrhage, postoperative, transurethral
ureter, 831 electrovaporization of prostate versus transurethral
Endothelial growth factor. See Vascular endothelial growth prostatic resection, 251
factor Hernia. See Inguinal hernia
Endourologic therapy of bladder calculi in kidney-pancreas Hormonal manipulation, induction, plus prostatectomy,
transplant recipients, +04 definitive irradiation, T3 prostate cancer, 782
Enterocele, vaginal evisceration as complication of, 128 Human papillomavirus type 18 deoxyribonucleic acid
Enterocystoplasty, sponge stopper for placement of immortalized prostate cell lines, expression of
urethrovesical sutures after, 1031 prostatic factors measured by reverse transcriptase
Enuresis. See Nocturnal enuresis polymerase chain reaction, 657
Epidermal growth factor, expression, prognosis of superficial Human papillomavirus type II, carcinoma of penis, 1046
bladder cancer, 640 Hydrocele, abdominoscrotal, in infancy, 5A-20
Epidermal growth factor receptor, expression, prognosis of Hydronephrosis, duplex system, prenatal diagnosis, renal
superficial bladder cancer, 640 salvage effects, 5A-23
Epididymectomy, testicular changes following, 333 Hypercalcemia, squamous cell carcinoma of bladder causing,
Erectile dysfunction 489
in aging, endothelial nitric oxide synthase, 516
therapeutic decision-making, radionuclide phallogram, '*°| interstitial radiotherapy, prostate cancer, comparison
5A-175 with radical prostatectomy, 884
therapy, health outcome measures, 861 Illumination system, Storz cold light, 5A-1
transurethral alprostadil, failed prior intracavernosal Immune system, urological malignancies treatment, 5A-41
injection therapy, 687 Immunodeficiencies, mice with, matrix metalloproteinase
Estrogen withdrawal, effect on nitric oxide synthase and tissue inhibitors of metalloproteinase families in
expression and apoptosis in rat vagina, 650 tumors transplanted in, 849
European Organization for Research and Treatment of Immunotherapy, oral bromocriptine, of bladder carcinoma
Cancer (EORTC) Prostate Cancer Trials 1976-1996, in situ after bacille Calmette-Guérin, 226
5A-50 Impotence, seminal vesicle resection during radical
retropubic prostatectomy and, 12
In situ hybridization, fluorescence, chromosome 9
Familial history, prostate cancer, prognostic variables,
aberrations by, of irrigation specimens from bladder
genetic biomarkers, recurrence after radical
cancer patients, 5A-58
prostatectomy, 970
Incontinence, urinary
Female
American Urological Association Symptom Index among
bladder outlet obstruction, proposed cutoff values to
men and women with, 213
define, 408
behavioral intervention, 2A-30, 2A-40
orthotopic diversion, cystectomy specimens, 951
biofeedback, 2A-35
stress urinary incontinence, CapSure (Re/Stor) continence
in children with myelodysplasia, placement of bladder
shield, 697
neck purse-string cuff, 1027
Filling symptoms, distinguished from voiding symptoms, in
economic costs, 355
benign prostatic hyperplasia, 422
in elderly, special considerations, 2A-20
Finasteride
electrical stimulation for, 2A-24
benign prostatic hyperplasia, 4A-46, 4A-51
epidemiology, pathophysiology, and evaluation, 2A-3
hematuria associated with, 237
orthotopic bladder diversion, 601
long-term effects, 677
outcome measures, 2A-11
prostate-specific antigen and prostate cancer detection,
post-prostatectomy, cost of conservative versus surgical
4A-59
management, 715
Fine needle aspiration of penis, transitional cell carcinoma
scope of problem, solutions on horizon, 2A-1
of bladder with mucinous differentiation, 1040
stress, CapSure (Re/Stor) continence shield, 697
Fractures. See Penile fractures
Infection, urinary tract. See Urinary tract infection
Inferior vena cava, absent, renal vein thrombosis secondary
Gender, age-related changes in lower urinary tract and, 206 to, 829
Gene therapy Infertility, male
guide to practicing urologists, 367 human sperm NADH and NADPH diaphorase
renal cell cancer, serum vascular endothelial growth factor cytochemistry, correlation with sperm motility, +64
as candidate biomarker of metastatic tumor response obstructive azoospermia treatment, 5A-150
to, 327 partial ejaculatory duct obstruction causing, 125
Germ cell tumor, testicular or extragonadal, lymphocele Inguinal hernia, sliding, obstructive uropathy, 1035
after retroperitoneal surgery mimicking occurrence, Interleukin-2 receptor, serum levels, in renal cell carcinoma,
833 145
Giant cell tumor, malignant osteoclast-like, of kidney, 495 Interleukin-8, in prostate cancer, 161]
Gleason score, biopsy, accuracy, observer variability, 525
Gore Tex tube grafts, failure of ureteral replacement with, Kaiser Permanente Health Care System, Southern California,
400 managed care, 5A-36
Grafts, buccal mucosal, for urethral reconstruction, 5A-15 Kallikrein, human glandular, monoclonal antibodies specific
Granins, prostate cancer, 5A-141 for, development, 804
UROLOGY 51 (6), 1998 1071
Ki-67, prostate cancer familial history, 970 pelvic, retroperitoneal and hepatic subcapsular extension,
Kidney after radical retropubic prostatectomy, 846
angiomyolipoma and oncocytoma association, 837
cystic disease, renal tubular dysfunction, 5A-156 MacLeod study, sperm count distribution in fertile men from
horseshoe 1971 to 1994, 86
blunt trauma to, arterial embolization for, 320 Magnetic resonance angiography, horseshoe kidney with
with ureteropelvic junction obstruction, magnetic ureteropelvic junction obstruction, +84
resonance urography and angiography, 484 Magnetic resonance imaging
laparoscopic cryosurgery, porcine model, 5A-161 endorectal coil
malignant osteoclast-like giant cell tumor, 495 locally advanced prostate cancer in clinically localized
multicystic dysplasia, cystic dysplasia of testis, 477 disease, 449
spiral computed tomography evaluation of, 3 prostate cancer volume response to neoadjuvant
androgen suppression therapy, 283
Laparoscopic cryosurgery, kidney, porcine model, 5A-161 renal transplant recipients with acquired cystic kidney
Laparoscopic examination, acute abdomen, postoperative disease, 534
urologic patient, 917 utility and cost, inconclusive scrotal lesions, 1018
Laparoscopic surgery Magnetic resonance urography
adrenalectomy, transabdominal and retroperitoneal horseshoe kidney with ureteropelvic junction obstruction,
approach, experience with, 29 484
pelvic node dissection, lymphocele after, 5A-131 Male. See also Infertility
resection of intra-abdominal testicular tumor, 122 lower urinary tract symptoms
varicocele ligation, versus subinguinal approach, 810 saw palmetto effects, 1003
Laparoscopy trends in management, 4A-1
contralateral patent processus vaginalis, 480 ultrasound estimated bladder weight correlation with
nonpalpable testicle, 5A-3 ultrasonic appearance of prostate and postvoid
Laser, Alexandrite, for treatment of renal and urethral residual urine, 722
calculi, safety and efficacy of, 33 prepubertal and pubertal bypass, idiopathic anterior
Laser prostatectomy urethritis in, 99
holmium laser resection versus neodymium:yttrium- Malpractice risks for urologists, 183
aluminum garnet visual laser ablation, 573 Managed care
potassium-titanyl-phosphate (KTP/532) vaporization, 254 impact on American urology, 5A-31
Laser thermal therapy, intraprostatic fiber placement to Southern California Kaiser Permanente Health Care
minimize thermal injury to prostatic urothelium System, 5A-36
during, 105 Mast cell growth factor receptor (c-kit), bladder, altered
Lateral fascia, initial dissection, positive margin rate in expression in interstitial cystitis, 939
radical prostatectomy, 766 Matrix metalloproteinase, in tumors transplanted in mice
Leiomyoma, epithelioid, bladder, voiding symptoms, 1037 with severe combined immunodeficiencies, 849
Leuprolide acetate, depot, prostate cancer, 271 McLellan, Frederick C., and clinical cytometrics, 168
Levofloxacin, complicated urinary tract infection, 610 Megaureter, primary obstructed and refluxed, of childhood,
Lithotripsy, electrohydraulic, bladder calculi in kidney- collagen subtypes, 820
pancreas transplant recipients, 404 Metalloproteinase families, tissue inhibitors of, in tumors
Lithotripsy, intracorporeal, renal and ureteral calculi, transplanted in mice with severe combined
Alexandrite laser for, 33 immunodeficiencies, 849
Lithotripsy, shock wave Microvessel density
signal generators, Medstone lithotripter, cardiac prediction of recurrence of stage T2 adenocarcinoma of
arrhythmias, 548 prostate, 73
stone growth after, neural network to predict, 335 renal cell carcinoma, 693
Lithotripsy, shock wave, extracorporeal Microwave antennae, Prostatron and Targis, benign prostatic
lower pole nephrolithiasis, 544 hyperplasia, 908
Lomefloxacin, complicated urinary tract infection, 610 Microwave thermoablation system, benign prostatic
Lower urinary tract hyperplasia, 731
age-related changes, gender and, 206 Microwave thermotherapy. See Thermotherapy
lesions, static cytometry and neural networks in Middle East, schistosomiasis incidence, 5A-170
discrimination of, 946 Mitomycin C, intravesical electromotive administration,
Lower urinary tract symptoms superficial bladder cancer, 506
health-related quality of life associated with, 428 Monoclonal antibodies
male '!!CYT-356, extraprostatic recurrent carcinoma after
current trends in management, 4A-1 prostatectomy, 978
saw palmetto effects, 1003 for human glandular kallikrein, development, 804
ultrasound estimated bladder weight correlation with transplantation antigens, 5A-146
ultrasonic appearance of prostate and postvoid Morbidity, in patients with orthotopic and heterotopic
residual urine, 722 urinary diversion, 51
minimally invasive alternative therapeutic options, 4A-32 Myelodysplasia, incontinence in children with, placement of
Lyell Sound, for suprapubic cystostomy, 103 bladder neck purse-string cuff, 1027
Lymphocele Myelomeningocele, urodynamic effects of oral oxybutynin
after laparoscopic pelvic node dissection, 5A-131 chloride in children with, 94
after retroperitoneal surgery for testicular or extragonadal
germ cell tumors, mimicking recurrence, 833 NADH diaphorase cytochemistry, sperm motility, 464
diagnosis and management, 5A-135 NADPH diaphorase cytochemistry, sperm motility, 464
1072 UROLOGY 51 (6), 1998
Nephrolithiasis, lower pole, extracorporeal shock wave Penile implant, intractable priapism, sickle cell disease, 638
lithotripsy, 544 Penis
Nephrotic syndrome, congenital, of Finnish type, 492 angiosarcoma of, 130
Netherlands, childhood nocturnal enuresis in, 1022 carcinoma, human papillomavirus type II association,
Neural networks 1046
in discrimination of low urinary system lesions, 946 fine needle aspiration, transitional cell carcinoma of
to predict stone growth after shock wave lithotripsy, 335 bladder with mucinous differentiation, 1040
Neuroendocrine cells, prostate cancer, 5A-121 Pentosanpolysulfate, interstitial cystitis, 381
Neuroendocrine differentiation, prostatic carcinoma during Peptides, derived from prostate-specific antigen, T cell
hormonal treatment, 585 recognition of, in prostate cancer, 150
Nitric oxide synthase Perineal needle tract seeding, in prostate cancer recurrence,
endothelial, erectile dysfunction in aging, 516 molecular correlation, 158
expression, effect of estrogen withdrawal on, 650 Peyronie’s disease plaque, intralesional verapamil, 620
Nocturnal enuresis, childhood, in the Netherlands, 1022 Phallogram, radionuclide, erectile dysfunction, 5A-175
Norepinephrine, prostate stroma cell phenotype modulation Pharmacologic options, for overactive bladder, 2A-43
by, 663 “Placebo effect,” in benign prostatic hyperplasia treatment
trials, conditional regression to the mean induced by
Obstructive uropathy, sliding inguinal hernia, 1035 censoring, 242
Oncocytoma, kidney, and angiomyolipoma, 837 Plaque, Peyronie’s disease, intralesional verapamil, 620
Oxybutynin chloride, oral, urodynamic effects in children Polymerase chain reaction
with myelomeningocele and detrusor hyperreflexia, candidemia in candiduria, 501
94 reverse transcriptase
expression of prostatic factors measured by, in human
papillomavirus type 18 deoxyribonucleic acid
ps3
expression, renal cell carcinoma, 1057 immortalized prostate cell lines, 657
immunohistochemical alterations in prostate cancer Polypropylene mesh, pubovaginal sling, 708
treated with radiation therapy, 346 Pouch function, effect of continent diversion after
prostate cancer familial history, 976 cystectomy in locally advanced bladder cancer on,
Pain syndromes 232
amitriptyline, 5A-179 Priapism
“mirror pain” as presentation of renal colic, 116 high flow
Palladium 103 brachytherapy, outpatient ultrasound-guided, malignant, with isolated metastasis to corpora
adenocarcinoma of prostate, 796 cavernosa, 324
Pancreas transplant. See Renal-pancreas transplant secondary to injury of cavernosal artery, imaging of,
Panning assays, antibodies to sperm detection, 5A-146 114
Parathyroid hormone, secretion, inhibition of, squamous cell intractable, sickle cell disease, penile implant for, 638
carcinoma of bladder causing, 489 ProstAsure Index, in detection of prostate cancer, 132
Parathyroid hormone-related protein, cell-specific Prostate
expression, normal and malignant prostate tissue, size, comparison in university and Veterans Affairs Health
5A-110 Care System patients with negative biopsies, +12
Patent processus vaginalis, laparoscopic evaluation, 480 stromal cell phenotype, modulation by norepinephrine,
Patient positioning, radical retropubic prostatectomy, 824 663
Pediatric urology transurethral resection, transurethral electrovaporization
abdominoscrotal hydrocele in infancy, 5A-20 versus, comparison of postoperative hemorrhage, 251
congenital nephrotic syndrome of Finnish type, 492 ultrasonic appearance, correlation with ultrasound
detrusorrhaphy for unilateral vesicoureteral reflux, 5A-12 estimated bladder weight, and postvoid residual urine
ectopia of both moieties of ureteral duplication anomalies, in men with lower urinary tract symptoms, 722
317 Prostate biopsy
idiopathic anterior urethritis in prepubertal and pubertal pathology trends of, 186
boys, 99 positive rate, age and prostate-specific antigen level, 531
intrarenal neuroblastoma masquerading as Wilms’ tumor, prostate-specific antigen density, intermediate serum PSA
313 level, in country with low prostate cancer incidence,
nocturnal enuresis in the Netherlands, 1022 5A-125
placement of bladder neck purse-string cuff, for sextant, radical prostatectomy stage, 759
incontinence in children with myelodysplasia, 1027 “suspicious for malignancy,” 749
prenatal diagnosis of duplex system hydronephrosis, effect Prostate cancer
on renal salvage, 5A-23 angiogenesis factors in, 161
primary obstructed and refluxed megaureter of childhood, familial history, prognostic variables, genetic biomarkers,
collagen subtypes, 820 recurrence after radical prostatectomy, 970
urethral valves, 5A-7 granin-A, 5A-141
urodynamic effects of oral oxybutynin chloride in hematolymphoid, transrectal ultrasound appearance, 339
children with myelomeningoccte and detrusor incidence and mortality, in Denmark, 590
hyperreflexia, 94 neuroendocrine differentiation
Pelvic node dissection, laparoscopic, lymphocele after, 5A- hormonal treatment, 585
131 morphological aspects, 5A-121
Penile arterial hemodynamics, penile ultrasonic occult, idiopathic thromboembolism as presenting sign,
velocitometry versus penile duplex ultrasonography, 775
89 specific T cell recognition of peptides derived from
Penile fractures, urethrography and cavernosography, 616 prostate-specific antigen in patients with, 150
UROLOGY 51 (6), 1998
Prostate cancer detection Prostate tissue, normal and malignant, cell-specific
endorectal coil magnetic resonance imaging, +49 expression of parathyroid hormone-related protein,
finasteride, 4A-59 5A-110
ProstAsure Index in, 132 Prostatectomy
Prostate cancer metastasis, age-related, 985 definitive irradiation, induction hormonal manipulation,
Prostate Cancer Prevention Trial, Army and Air Force T3 prostate cancer, 782
leadership in, 4A-65 laser. See Laser prostatectomy
Prostate cancer recurrence urinary incontinence, cost of conservative versus surgical
adenocarcinoma, stage T2, microvessel density analysis, management, 715
73 Prostatectomy, laser. See Laser prostatectomy
'tCYT-356 localization, 978 Prostatectomy, radical
factors predicting, 283 biopsy-selected nerve sparing, incidence of positive
perineal needle tract seeding in, molecular correlation, surgical margins after, 437
158 '*°1 interstitial radiotherapy comparison with, 884
salvage surgery, 789 positive margin rate, initial dissection of lateral fascia, 766
Prostate cancer screening, free serum prostate-specific sponge stopper for placement of urethrovesical sutures
antigen, 558 after, 1031
Prostate cancer staging, biological classification as stage, sextant biopsies to predict, 759
alternative to, 265 Prostatectomy, radical perineal, versus radical retropubic,
Prostate cancer treatment. See also Radiotherapy prostate-specific antigen, 277
accuracy in selecting patients, 197 Prostatectomy, radical retropubic
androgen deprivation, 137 ambulatory, 443
endorectal coil magnetic resonance imaging, tumor bladder neck preservation during, impact on pathologic
volume assessment, 283 outcome, anastomotic strictures, and continence, 73
continent nerve preservation, urinary continence, 960
Casodex compared with castration, 389
patient positioning, 824
external beam radiotherapy, for stage T1/T2, 258
versus radical perineal, prostate-specific antigen, 277
leuprolide acetate depot, 271
retroperitoneal and hepatic subcapsular extension of
outpatient ultrasound-guided palladium 103
pelvic lymphocele after, 846
brachytherapy, 796
seminal vesicle resection during, 12
radiation therapy failures, p53 and bcl-2
urinary continence after, puboprostatic ligament sparing
immunohistochemical alterations, 346
improvement of, 67
shared decision making in, 63
Prostatic factors, expression, human papillomavirus type 18
T3, irradiation, induction hormonal manipulation plus
deoxyribonucleic acid immortalized prostate cell
prostatectomy, 782
lines, reverse transcriptase polymerase chain reaction
Prostate cancer trials
measurement, 657
European Organization for Research and Treatment of
Prostatic hyperplasia, benign
Cancer (EORTC) Prostate Cancer Trials 1976-1996,
accurate determination of prostate size via DRE and
5A-50
TRUS, 4A-19
Prostate-specific antigen
acute urinary retention in, transition zone index as risk
density, intermediate serum PSA level, in country with
factor, 595
low prostate cancer incidence, 5A-125
American Urological Association Symptom Index for, 213
finasteride effects, 4A-59
comprehensive patient evaluation, 4A-13
free
current trends in management, 4A-1
in detection of prostate cancer, 132
distinction between symptoms of voiding and filling, 422
testing, 5A-98
finasteride, 677, 4A-46
levels hematuria associated with, effects of finasteride on, 237
endorectal coil magnetic resonance imaging, 449 male pattern baldness, 744
positive prostate biopsy, age, 531 medical management, 4A-38
peptides derived from, T cell recognition of, in prostate long-term implications, 4A-51
cancer, 150 microwave thermoablation, 731
positive biopsy, 283 microwave thermotherapy, with the Dornier Urowave for,
post-prostatectomy nadir, salvage radiotherapy, 998 19
radical perineal prostatectomy versus radical retropubic minimally invasive alternative therapeutic options, 4A-32
prostatectomy, 277 natural history and epidemiology, +A-8
serum surgical management developments, 4A-23
effect of ejaculation, in prostate cancer-screening tamsulosin, 861, 892, 901
population, 455 thermal treatment
following radiotherapy for prostate cancer, failure Prostatron and Targis microwave antennae, 908
patterns and definition of cure, 566 transurethral microwave, 1008
in men without prostate cancer, race differences in, 300 transurethral needle ablation, 415
pathologic features of prostate cancer, 558 treatment trials, “placebo effect” in, conditional regression
total, elimination, from serum, compared with PSA to the mean induced by censoring, 242
complexed to alpha,-antichymotrypsin, 57 Vaportrode transurethral vaporization of prostate, 1013
volume, influence on noncancerous prostatic tissue, 293 voiding dysfunction in, 5A-62, 5A-73
Prostate-specific antigen immunoassay, standardization, Prostatic tissue, noncancerous, influence on prostate-specific
current status, future directions, 5A-83 antigen volume, 293
Prostate-specific membrane antigen, measurement, 5A-89 Prostatism, natural history of, 213
1074 UROLOGY 51 (6), 1998